The Global Health Body Sounds Alert Over Acute Scarcity of Obesity Jabs
Under one in 10 individuals eligible to benefit from GLP-1 drugs including Wegovy can access them, states the World Health Organization as it publishes its inaugural recommendations on the therapies.
With in excess of 1,000,000,000 people worldwide currently living with obesity, it is calling for increased and just access to GLP-1 medication.
Based on projections, in excess of 2,000,000,000 will be obese by 2030 without intervention.
"The latest guidance acknowledges that excess weight is a lifelong illness that can be managed with thorough and lifelong treatment," stated its chief Tedros Adhanom Ghebreyesus.
Significant expense, insufficient output, and distribution challenges are significant obstacles to universal access to the treatments that can assist patients in reducing substantial body mass, says the body.
Weight-Loss Drug Supply Crisis
Even in the current best projected scenario, the supply of GLP-1 therapies would only suffice for about 100 million people – under 10% of eligible patients, according to the health organization.
The advice calls on governments and firms to widen access, by approaches like voluntary licensing.
A patent on the active ingredient – the primary component of a leading brand – is scheduled to end in a number of nations in 2026.
How Obesity Drugs Work
GLP-1 drugs imitate a biological compound to delay gastric emptying, reduce hunger and boost the sense of being full so users reduce food intake.
Patients commonly start to lose weight after several weeks of commencing the weekly injections.
Evidence indicates people may regain a significant portion within a year of stopping the drug, because their normal food cravings resume.
To be carrying excess weight elevates your risk for contracting medical conditions, such as type 2 diabetes, heart disease, stroke, and some malignancies.
Obesity affects people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.
